Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com - WBOC-TV 16, Delmarvas News Leader, FOX 21 -

Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com

Posted:

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

SOURCE:

New research report Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market elaborated by GBI Research is now available at MarketPublishers.com. According to the study, the NSCLC Market in top 8 developed nations is predicted to see a 6.6% CAGR through 2020.

London, UK (PRWEB) August 20, 2014

The non-small cell lung cancer (NSCLC) market value is expected to increase considerably in the offing across the top 8 developed nations, from just over USD 5.1 billion as of 2013 to around USD 8 billion by 2020-end, posting a CAGR of 6.6% during the forecasted period. The growth is projected to be driven by innovative therapies entering the squamous cell carcinoma (SCC) segment, which is currently lacking efficient treatment, unlike the non-squamous segment. Thus, patients with SCC are expected to benefit from key initial (first-line) and additional (second-line) therapies in the form of Yervoy (ipilimumab) and nivolumab, having relied on generic chemotherapy for the last ten years. Non-squamous patients, on the other hand, have some successful mutation-specific therapies, like Tarceva (erlotinib), and histology-specific therapies, like Alimta (pemetrexed), and which are already marketed. New additional entrants will create a highly competitive environment. The generic erosion of such leaders as Alimta and Tarceva in the offing is set to create a tough situation for novel products that have exhibited only slight improvements in efficacy or safety.

In spite of the therapeutic potential of targeted therapies and the discovery of a number of promising molecular targets, these products development remains in the early stage pipeline. Anaplastic lymphoma kinase (ALK) mutations and epidermal growth factor receptor (EGFR) are anticipated to remain the only identified intracellular molecular aberrations targeted by marketed products. Instead, the late stage pipeline is mainly occupied by immunotherapeutic procedures which still offer a larger degree of specificity than chemotherapies; however, they initiate the destruction of tumour cells via the immune system. Phase III immunotherapies like Yervoy (ipilimumab), necitumumab and nivolumab are expected to reach the market in the next few years, each with a specific target.

New research report Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market elaborated by GBI Research is now available at MarketPublishers.com.

Report Details:

Title: Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market
Published: July, 2014
Pages: 143
Price: US$ 3,500.00
http://marketpublishers.com/report/diagnostics-diseases/cancer/non-small-cell-lung-cancer-market-to-2020-new-therapies.html

The report provides a comprehensive understanding of NSCLC as both a disease and as a marketplace across the leading geographies North America, top 5 EU countries and Japan, examining the current NSCLC market and forecasting key market trends to 2020. The research study focuses on the increasing differentiation among the 3 main NSCLC sub-types adenocarcinoma, squamous cell and large cell carcinoma. It provides an overview of the disease; comparisons of the safety and efficacy of the high-potential brands in the NSCLC market alongside identifying the unmet needs of the treatment for the disease; analysis of the NSCLC clinical trial landscape (molecule type, drug distribution by phase and MoA, etc.) plus profiles and forecasts for the pipeline drugs with high potential; epidemiological forecasts of the leading NSCLC markets; forecasting model for the NSCLC sector, considering the actual marketed therapies alongside the potential entry of novel products to the market; analysis of co-development and licensing agreements within the NSCLC indication. Furthermore, an all-round analysis of the factors driving and restraining the NSCLC markets development can also be found in the research report.

Reasons to Buy:

  •     Gain a comprehensive understanding of the NSCLC pipeline and the clinical needs being addressed by it.
  •     Get a clear idea of the leading products that may come into the market before 2020 by examining their profiles and focusing on their clinical research performance, and also on how they can be used in treating NSCLC alongside the level of the competition they enter.
  •     Evaluate the risk related to NSCLC product development profiled by molecule type and mechanism of action (MOA) and compared with industry and therapy-area averages alike; moreover, with the help of extensive data analyses, develop a more refined understanding of the major trends in trial size and duration for specific MOA or molecule types.
  •     Identify growth patterns in the NSCLC market through to 2020 and get to know the underlying causes, as well as observe the contributions made by each of the leading markets and/or late-stage pipeline medicines to this growth.

More in-demand market research reports by the publisher can be found at GBI Research page.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/08/prweb12107850.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

Powered by WorldNow

All content © Copyright 2000 - 2014 Worldnow and WBOC. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service